HomeRTI • FRA
Follow
Revance Therapeutics Inc
Previous close
€4.80
Day range
€4.44 - €4.44
Year range
€4.44 - €33.20
Market cap
513.09M USD
Avg Volume
65.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 69.80M | 39.82% |
Operating expense | 85.91M | 5.43% |
Net income | -55.70M | 61.84% |
Net profit margin | -79.80 | 72.71% |
Earnings per share | -0.61 | 67.97% |
EBITDA | -52.53M | 6.60% |
Effective tax rate | 0.00% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 253.92M | -25.47% |
Total assets | 478.45M | -17.78% |
Total liabilities | 630.06M | 10.67% |
Total equity | -151.60M | — |
Shares outstanding | 88.21M | — |
Price to book | -2.79 | — |
Return on assets | -26.68% | — |
Return on capital | -38.07% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -55.70M | 61.84% |
Cash from operations | -42.73M | -41.58% |
Cash from investing | 2.37M | -94.21% |
Cash from financing | -1.63M | 73.61% |
Net change in cash | -41.99M | -1,011.83% |
Free cash flow | -9.73M | -19.01% |
About
Founded
1999
Headquarters
Website
Employees
597